A. Zhou

Individual isotoxic radiation dose escalation based on V20 and advanced technologies benefits unresectable stage III non-small cell lung cancer patients treated with concurrent chemoradiotherapy: long term follow-up

Baosheng Li, Zhong-tang Wang, Hong-fu Sun, 2017, Oncotarget.

1207P Neoadjuvant PD-L1 inhibitor (socazolimab) plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma (ESCC): A multicenter, randomized, double-blind phase II study

Y. Fang, S. Wang, H. Chen, 2022, Annals of Oncology.

Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study.

A. Zhou, T. Sun, X.Q. Yan, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.